PTK2B and acute myeloid leukemia: The main goal of the present study was to evaluate the protein tyrosine kinase (PTK) profiles of primary leukemic cells in patients with KMT2A/MLL-R+ AML and ALL as potential therapeutic targets to overcome cancer drug resistance.